Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)
Phase 3
Completed
NCT04965636
| Condition | Hypereosinophilic Syndrome |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | GlaxoSmithKline |
|---|
| Status | Completed |
|---|
| Enrollment | 16 participants |
|---|
| Interventions | Mepolizumab |
|---|
| Start date | Jul 14, 2022 |
|---|
| Completion date | Oct 28, 2025 |
|---|
| Results posted | May 4, 2026 |
|---|
Summary
The purpose of this study is to investigate the efficacy and safety of mepolizumab in children and adolescents with hypereosinophilic syndrome (HES) who are receiving standard of care (SoC) therapy.
Number of Participants Who Experienced HES Flares Over the 52-Week Study Treatment Period
Up to Week 52 · Participants
| Mepolizumab 100 mg SC | 10 Participants |
|---|
| Mepolizumab 300 mg SC | 4 Participants |
|---|
| Mepolizumab 200/100 mg SC | 1 Participants |
|---|
| Mepolizumab 200/300 mg SC | 1 Participants |
|---|
| Mepolizumab 100 mg SC | 0 Participants |
|---|
| Mepolizumab 300 mg SC | 0 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.